|
|||||
|
|
| Latest Insider Trading | Top Insider Trading Recent Week | Top 10% Owner Trading Recent Week | Filter
|
| Ticker | Owner | Relationship | Date | Transaction | Cost |
#Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| DBVT | Mohideen Pharis | Chief Medical Officer | Nov 20 '25 | Sale | 2.88 | 6,496 | 18,708 | 103,153 | Nov 25 04:15 PM |
| DBVT | Mohideen Pharis | Chief Medical Officer | Nov 21 '25 | Sale | 2.77 | 1,624 | 4,498 | 101,529 | Nov 25 04:15 PM |
| DBVT | Mohideen Pharis | Chief Medical Officer | Jul 29 '25 | Sale | 2.22 | 464 | 1,030 | 109,649 | Jul 31 04:15 PM |
| DBVT | Mohideen Pharis | Chief Medical Officer | May 22 '25 | Sale | 1.84 | 397 | 730 | 110,113 | May 27 04:10 PM |
| DBVT | Mohideen Pharis | Chief Medical Officer | Jan 30 '25 | Sale | 0.85 | 600 | 510 | 110,510 | Jan 31 04:59 PM |
| DBVT | Mohideen Pharis | Chief Medical Officer | Nov 22 '24 | Sale | 0.53 | 342 | 181 | 111,675 | Nov 27 04:15 PM |
| DBVT | Mohideen Pharis | Chief Medical Officer | Nov 25 '24 | Sale | 0.57 | 565 | 322 | 111,110 | Nov 27 04:15 PM |
| DBVT | Mohideen Pharis | Chief Medical Officer | Nov 21 '24 | Sale | 0.54 | 2,350 | 1,269 | 112,017 | Nov 25 05:13 PM |
| DBVT | Mohideen Pharis | Chief Medical Officer | Jul 29 '24 | Sale | 0.98 | 1,785 | 1,749 | 79,367 | Jul 31 05:32 PM |
| DBVT | Mohideen Pharis | Chief Medical Officer | May 22 '24 | Sale | 1.38 | 382 | 527 | 81,812 | May 29 04:15 PM |
| DBVT | Mohideen Pharis | Chief Medical Officer | May 24 '24 | Sale | 1.36 | 660 | 898 | 81,152 | May 29 04:15 PM |
| DBVT | Mohideen Pharis | Chief Medical Officer | Nov 22 '23 | Sale | 1.74 | 2,245 | 3,906 | 82,194 | Dec 19 04:44 PM |
| DBVT | Mohideen Pharis | Chief Medical Officer | Nov 24 '22 | Sale | 2.88 | 1,792 | 5,161 | 49,908 | Aug 14 04:32 PM |
| DBVT | Mohideen Pharis | Chief Medical Officer | May 24 '23 | Sale | 3.54 | 469 | 1,660 | 49,439 | Aug 14 04:32 PM |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite